FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1505327414> ?p ?o ?g. }

• W1505327414 endingPage "466" @default.
• W1505327414 startingPage "458" @default.
• W1505327414 abstract "WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Renin‐angiotensin‐aldosterone system inhibition confers cardio‐renal protection and may be achieved by monotherapy with an angiotensin enzyme converting inhibitor (ACEI) or an angiotensin‐II receptor blocker (ARB). • Dual ACEI and ARB therapy has been examined in major clinical trials with conflicting results. • The prescribing pattern of dual therapy in general primary care population is not known. WHAT THIS STUDY ADDS • An increase in the co‐prescribing of ACEIs and ARBs was observed in the Irish primary care population. • Co‐prescribing of ACEIs and ARBs in the primary care population did not appear to be influenced by results from major clinical trials. • ACEIs and ARBs were more likely to be co‐prescribed in special cohorts of the population with diabetes, hypertension and heart failure. AIMS (i) To examine the trends in co‐prescribing of angiotensin converting enzyme inhibitor (ACEI) and angiotensin‐II receptor blocker (ARB) therapy and (ii) to examine the influence of major clinical trials (CALM, COOPERATE, VALIANT and ONTARGET) on co‐prescribing. METHODS The Irish HSE‐Primary Care Reimbursement Services database was used to identify patients ≥16 years old co‐prescribed ACEIs and ARBs between January 2000 and April 2009 ( n = 266 554 prescriptions). The rate of prescribing per 1000 general medical services (GMS) scheme population was calculated for each month. Patients with diabetes, hypertension, heart failure and ischaemic heart disease were also identified by prescribing of certain medications. A linear trend test was used to examine prescribing trends. Logistic regression was used to examine prescribing according to patient characteristics. The effects of the major trials on prescribing were examined using segmented regression analysis for 12 months pre‐ and post‐trials. RESULTS There was a significant linear trend in overall ACEI and ARB co‐prescribing over the study period ( P < 0.001). Rate of co‐prescribing in January 2000 and April 2009 was 0.16 and 5.72, per 1000 eligible population, respectively. Those 45–64 years old (OR = 2.88, 95% confidence interval (CI) 2.71, 3.06) and ≥65 years (OR = 2.52, 95% CI 2.36, 2.68) were more likely to receive dual therapy compared with those <45 years old. Those with hypertension (OR = 8.85, 95% CI 8.45, 9.27), diabetes (OR = 4.10, 95% CI 3.97, 4.23) and heart failure (OR = 1.78, 95% CI 1.72, 1.84) were more likely to receive dual therapy compared with the general population. Significant increases in prescribing were observed only after the CALM ( P = 0.03) and VALIANT ( P = 0.007) trials. CONCLUSION Increased co‐prescribing of ACEIs and ARBs was observed in Ireland during 2000–09. Prescribing patterns did not appear to be affected by results from major trials." @default.
• W1505327414 created "2016-06-24" @default.
• W1505327414 creator A5015600063 @default.
• W1505327414 creator A5062853842 @default.
• W1505327414 creator A5065110957 @default.
• W1505327414 creator A5071885054 @default.
• W1505327414 date "2011-02-01" @default.
• W1505327414 modified "2023-10-17" @default.
• W1505327414 title "Trends in co-prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland" @default.
• W1505327414 cites W1759612827 @default.
• W1505327414 cites W1983481977 @default.
• W1505327414 cites W1985534800 @default.
• W1505327414 cites W2002839070 @default.
• W1505327414 cites W2005691625 @default.
• W1505327414 cites W2012003405 @default.
• W1505327414 cites W2024283034 @default.
• W1505327414 cites W2024428393 @default.
• W1505327414 cites W2026021204 @default.
• W1505327414 cites W2026382161 @default.
• W1505327414 cites W2029190141 @default.
• W1505327414 cites W2032953543 @default.
• W1505327414 cites W2042353763 @default.
• W1505327414 cites W2048325526 @default.
• W1505327414 cites W2056893352 @default.
• W1505327414 cites W2084130497 @default.
• W1505327414 cites W2084343172 @default.
• W1505327414 cites W2098780362 @default.
• W1505327414 cites W2099737510 @default.
• W1505327414 cites W2100409734 @default.
• W1505327414 cites W2110132657 @default.
• W1505327414 cites W2117254307 @default.
• W1505327414 cites W2121490027 @default.
• W1505327414 cites W2123371599 @default.
• W1505327414 cites W2125316432 @default.
• W1505327414 cites W2130567407 @default.
• W1505327414 cites W2139898950 @default.
• W1505327414 cites W2143144750 @default.
• W1505327414 cites W2146582345 @default.
• W1505327414 cites W2152798629 @default.
• W1505327414 cites W2159929435 @default.
• W1505327414 cites W2168907840 @default.
• W1505327414 cites W2181350280 @default.
• W1505327414 cites W2305718992 @default.
• W1505327414 cites W2912928282 @default.
• W1505327414 doi "https://doi.org/10.1111/j.1365-2125.2010.03835.x" @default.
• W1505327414 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3045556" @default.
• W1505327414 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21284706" @default.
• W1505327414 hasPublicationYear "2011" @default.
• W1505327414 type Work @default.
• W1505327414 sameAs 1505327414 @default.
• W1505327414 citedByCount "8" @default.
• W1505327414 countsByYear W15053274142012 @default.
• W1505327414 countsByYear W15053274142014 @default.
• W1505327414 countsByYear W15053274142017 @default.
• W1505327414 countsByYear W15053274142018 @default.
• W1505327414 countsByYear W15053274142020 @default.
• W1505327414 countsByYear W15053274142021 @default.
• W1505327414 countsByYear W15053274142023 @default.
• W1505327414 crossrefType "journal-article" @default.
• W1505327414 hasAuthorship W1505327414A5015600063 @default.
• W1505327414 hasAuthorship W1505327414A5062853842 @default.
• W1505327414 hasAuthorship W1505327414A5065110957 @default.
• W1505327414 hasAuthorship W1505327414A5071885054 @default.
• W1505327414 hasBestOaLocation W15053274142 @default.
• W1505327414 hasConcept C104849204 @default.
• W1505327414 hasConcept C126322002 @default.
• W1505327414 hasConcept C134018914 @default.
• W1505327414 hasConcept C164705383 @default.
• W1505327414 hasConcept C177713679 @default.
• W1505327414 hasConcept C2426938 @default.
• W1505327414 hasConcept C27016395 @default.
• W1505327414 hasConcept C2778198053 @default.
• W1505327414 hasConcept C2779611605 @default.
• W1505327414 hasConcept C2779888176 @default.
• W1505327414 hasConcept C2908647359 @default.
• W1505327414 hasConcept C2908929049 @default.
• W1505327414 hasConcept C535046627 @default.
• W1505327414 hasConcept C555293320 @default.
• W1505327414 hasConcept C71924100 @default.
• W1505327414 hasConcept C84393581 @default.
• W1505327414 hasConcept C98274493 @default.
• W1505327414 hasConcept C99454951 @default.
• W1505327414 hasConceptScore W1505327414C104849204 @default.
• W1505327414 hasConceptScore W1505327414C126322002 @default.
• W1505327414 hasConceptScore W1505327414C134018914 @default.
• W1505327414 hasConceptScore W1505327414C164705383 @default.
• W1505327414 hasConceptScore W1505327414C177713679 @default.
• W1505327414 hasConceptScore W1505327414C2426938 @default.
• W1505327414 hasConceptScore W1505327414C27016395 @default.
• W1505327414 hasConceptScore W1505327414C2778198053 @default.
• W1505327414 hasConceptScore W1505327414C2779611605 @default.
• W1505327414 hasConceptScore W1505327414C2779888176 @default.
• W1505327414 hasConceptScore W1505327414C2908647359 @default.
• W1505327414 hasConceptScore W1505327414C2908929049 @default.
• W1505327414 hasConceptScore W1505327414C535046627 @default.
• W1505327414 hasConceptScore W1505327414C555293320 @default.
• W1505327414 hasConceptScore W1505327414C71924100 @default.
• W1505327414 hasConceptScore W1505327414C84393581 @default.

• next